These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 9766508

  • 1. Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin's lymphoma--phase I/II studies and pharmacokinetics.
    Braess J, Freund M, Hanauske A, Heil G, Kaufmann C, Kern W, Schüssler M, Hiddemann W, Schleyer E.
    Leukemia; 1998 Oct; 12(10):1618-26. PubMed ID: 9766508
    [Abstract] [Full Text] [Related]

  • 2. Response to cytarabine ocfosfate (YNK01) in a patient with chronic lymphocytic leukemia refractory to treatment with chlorambucil/prednisone, fludarabine, and prednimustine/mitoxantrone.
    Braess J, Kern W, Unterhalt M, Kaufmann CC, Ramsauer B, Schüssler M, Kaeser-Fröhlich A, Hiddemann W, Schleyer E.
    Ann Hematol; 1996 Oct; 73(4):201-4. PubMed ID: 8890711
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics of Ara-CMP-Stearate (YNK01): phase I study of the oral Ara-C derivative.
    Schleyer E, Braess J, Ramsauer B, Unterhalt M, Kaufmann C, Wilde S, Schüssler M, Hiddemann W.
    Leukemia; 1995 Jun; 9(6):1085-90. PubMed ID: 7596174
    [Abstract] [Full Text] [Related]

  • 4. [A case of complete remission from acute unclassified leukemia achieved by using a prodrug of ara C, stearyl-ara-CMP (YNK01)].
    Nishikawa M, Morita K, Komada F, Uemura Y, Kageyama S, Minami N, Deguchi K, Shirakawa S.
    Gan No Rinsho; 1990 Oct; 36(12):2204-9. PubMed ID: 2232191
    [Abstract] [Full Text] [Related]

  • 5. [Phase I study of YNK01 (1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate)].
    Fukuoka M, Miyazaki T, Yoshida Y, Hattori M, Niitani H, Nakamura T, Hirota Y, Ohta K, Tanaka M, Suzuoki Y.
    Gan To Kagaku Ryoho; 1990 Nov; 17(11):2213-9. PubMed ID: 2241185
    [Abstract] [Full Text] [Related]

  • 6. Treatment of patients with advanced chronic myelogenous leukemia with interferon-alpha-2b and continuous oral cytarabine ocfosfate (YNK01): a pilot study.
    Kühr T, Eisterer W, Apfelbeck U, Linkesch W, Bechter O, Zabernigg A, Geissler K, Barbieri G, Duba C, Gastl G, Thaler J.
    Leuk Res; 2000 Jul; 24(7):583-7. PubMed ID: 10867132
    [Abstract] [Full Text] [Related]

  • 7. [Phase II study of YNK01 (1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate) on hematological malignancies].
    Tatsumi N, Yamada K, Ohshima T, Nakamura T, Ohno R, Masaoka T, Kimura I, Kimura K.
    Gan To Kagaku Ryoho; 1990 Dec; 17(12):2387-95. PubMed ID: 2260876
    [Abstract] [Full Text] [Related]

  • 8. Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon alpha-2b for the treatment of chronic myelogenous leukemia patients in chronic phase.
    Maloisel F, Guerci A, Guyotat D, Ifrah N, Michallet M, Reiffers J, Tertain G, Blanc M, Bauduer F, Brière J, Abgrall JF, Pegourie-Bandelier B, Solary E, Cambier N, Coso D, Vilque JP, Delain M, Harousseau JL, Rousselot P, Belhadj K, Morice P, Attal J, Chabin M, Chastang C, Guilhot J, Guilhot F, France Intergroupe des Leucémies Myéloïdes Chroniques.
    Leukemia; 2002 Apr; 16(4):573-80. PubMed ID: 11960335
    [Abstract] [Full Text] [Related]

  • 9. Differences in the intracellular pharmacokinetics of cytosine arabinoside (AraC) between circulating leukemic blasts and normal mononuclear blood cells.
    Hiddemann W, Schleyer E, Unterhalt M, Zühlsdorf M, Rolf C, Reuter C, Kewer U, Uhrmeister C, Wörmann B, Büchner T.
    Leukemia; 1992 Dec; 6(12):1273-80. PubMed ID: 1453772
    [Abstract] [Full Text] [Related]

  • 10. Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison.
    Kern W, Aul C, Maschmeyer G, Schönrock-Nabulsi R, Ludwig WD, Bartholomäus A, Bettelheim P, Wörmann B, Büchner T, Hiddemann W.
    Leukemia; 1998 Jul; 12(7):1049-55. PubMed ID: 9665189
    [Abstract] [Full Text] [Related]

  • 11. Continuous oral cytarabine ocfosfate with interferon-alpha-2b for patients with newly diagnosed chronic myeloid leukaemia: a pilot study.
    del Cañizo MC, Fisac MP, Galende J, Hurtado JA, Moro MJ, Rodriguez JA, Rivas JM, Tabernero MD, Castellano-Leonés Group on CML.
    Br J Haematol; 2001 Dec; 115(3):541-4. PubMed ID: 11736933
    [Abstract] [Full Text] [Related]

  • 12. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
    Chabot GG, Armand JP, Terret C, de Forni M, Abigerges D, Winograd B, Igwemezie L, Schacter L, Kaul S, Ropers J, Bonnay M.
    J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
    [Abstract] [Full Text] [Related]

  • 13. [Antitumor activity of a novel analog of cytarabine, 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone 5'-(sodium octadecyl phosphate) monohydrate (YNK01)].
    Nagahata T, Shibasaki C, Ishii T, Uchida T, Arakawa M, Kusama K, Ekimoto H, Takahashi K.
    Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1437-45. PubMed ID: 2389942
    [Abstract] [Full Text] [Related]

  • 14. Clinical pharmacology of 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate, an orally administered long-acting derivative of low-dose 1-beta-D-arabinofuranosylcytosine.
    Ueda T, Kamiya K, Urasaki Y, Wataya S, Kawai Y, Tsutani H, Sugiyama M, Nakamura T.
    Cancer Res; 1994 Jan 01; 54(1):109-13. PubMed ID: 8261429
    [Abstract] [Full Text] [Related]

  • 15. [Plasma concentration of cytosine arabinoside (Ara-C) in the elderly patients with hematological malignancy treated by Ara-C or cytarabine ocfosfate (SPAC)].
    Tsutsumi H, Kumakawa T, Hirai M, Kikukawa M, Arie Y, Mori M, Kodo H, Nakamura N, Murai Y, Mizutani R.
    Nihon Ronen Igakkai Zasshi; 1995 Mar 01; 32(3):190-4. PubMed ID: 7596061
    [Abstract] [Full Text] [Related]

  • 16. High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias. Results of a clinical phase II study.
    Kern W, Schleyer E, Unterhalt M, Wörmann B, Büchner T, Hiddemann W.
    Cancer; 1997 Jan 01; 79(1):59-68. PubMed ID: 8988727
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics of high-dose cytarabine and its deamination product--a reappraisal.
    Burk M, Heyll A, Arning M, Volmer M, Fartash K, Schneider W.
    Leuk Lymphoma; 1997 Oct 01; 27(3-4):321-7. PubMed ID: 9402329
    [Abstract] [Full Text] [Related]

  • 18. Optimizing therapy for acute myeloid leukemia based on differences in intracellular metabolism of cytosine arabinoside between leukemic blasts and normal mononuclear blood cells.
    Hiddemann W, Schleyer E, Unterhalt M, Kern W, Büchner T.
    Ther Drug Monit; 1996 Aug 01; 18(4):341-9. PubMed ID: 8857548
    [Abstract] [Full Text] [Related]

  • 19. [A pharmacokinetic study of the value of oral cytarabine ocfosfate in the treatment of hematological malignancies].
    Ueda Y, Mori S, Ito T, Maesako Y, Konishi H, Yagiri Y.
    Rinsho Ketsueki; 1998 May 01; 39(5):348-54. PubMed ID: 9637884
    [Abstract] [Full Text] [Related]

  • 20. Interferon-alpha-2b and oral cytarabine ocfosfate for newly diagnosed chronic myeloid leukaemia.
    Mollee P, Arthur C, Hughes T, Januszewicz H, Grigg A, Bradstock K, Wolf M, Gibson J, Schwarer AP, Spencer A, Browett P, Hawkins T, Seldon M, Herrmann R, Watson A, Seymour JF, Martin N, Shina S, Low C, Wright S, Rodwell R, Coulston J, Morton J, Blacklock H, Taylor D, Taylor KM.
    Ann Oncol; 2004 Dec 01; 15(12):1810-5. PubMed ID: 15550587
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.